The Department of Epidemiology and Preventive Medicine, Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Diabetes and Vascular Medicine Unit, Monash Health, Clayton, Victoria, Australia.
Hum Reprod Update. 2018 Jul 1;24(4):455-467. doi: 10.1093/humupd/dmy007.
Our prior meta-analyses demonstrated an increased prevalence of impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) with polycystic ovary syndrome (PCOS), but with substantial clinical heterogeneity.
We aimed to update our previous review to quantify the prevalence of IGT and T2DM in PCOS with only quality studies (good and fair quality). We also aimed to examine the contribution of parameters including ethnicity, obesity and method of diagnosing T2DM in explaining the observed heterogeneity in IGT and T2DM prevalence in PCOS.
We conducted a literature search (MEDLINE, CINAHL, EMBASE, clinical trial registries and hand-searching) up to June 2016 to identify studies reporting the prevalence of dysglycemia (IGT and T2DM) in women with and without PCOS. We included studies where women with PCOS (defined according to original National Institute of Health) were compared to women without PCOS for the end-points of the prevalence of IGT or T2DM. We excluded case reports, case series, editorials, and narrative reviews. Studies where PCOS was diagnosed by self-report, or where IGT or T2DM were measured by fasting glucose, only were excluded. We assessed the methodological quality of the included studies using a priori criteria based on the Newcastle-Ottawa Scaling (NOS) for non-randomized studies. Data are presented as odds ratio (OR) (95% CI) with random-effects meta-analysis by Mantel-Haenszel methods. We assessed the contribution of demographic and clinical factors to heterogeneity using subgroup and meta-regression analysis.
We reviewed 4530 studies and included 40 eligible studies in the final analysis. On meta-analysis of quality studies, women with PCOS had an increased prevalence of IGT (OR = 3.26, 95% CI: 2.17-4.90) and T2DM (OR = 2.87, 95% CI: 1.44-5.72), which differed by ethnicity (for IGT, Asia: 5-fold, the Americas: 4-fold and Europe: 3-fold), was higher with obesity, and doubled among studies using self-report or administrative data for diagnosing diabetes. The ethnicity-related difference retained its significance for Asia and Europe in BMI-matched subgroups. Clear contributors to heterogeneity did not emerge in meta-regression.
Our findings underscore the importance of PCOS as a cause of dysglycemia with a higher prevalence of IGT and T2DM. They support the relevance of ethnicity and obesity and emphasize the need for accurate diagnostic methods for diabetes.
CRD42017056524.
我们之前的荟萃分析表明,多囊卵巢综合征(PCOS)患者葡萄糖耐量受损(IGT)和 2 型糖尿病(T2DM)的患病率增加,但存在较大的临床异质性。
我们旨在更新之前的综述,以量化仅质量研究(良好和中等质量)中 PCOS 患者 IGT 和 T2DM 的患病率。我们还旨在检查参数,包括种族、肥胖和诊断 T2DM 的方法在解释 PCOS 患者 IGT 和 T2DM 患病率观察到的异质性方面的作用。
我们进行了文献检索(MEDLINE、CINAHL、EMBASE、临床试验注册处和手工检索),截至 2016 年 6 月,以确定报告患有和不患有 PCOS 的女性中糖基化受损(IGT 和 T2DM)患病率的研究。我们纳入了将多囊卵巢综合征患者(根据原始国立卫生研究院定义)与无多囊卵巢综合征患者进行比较的研究,以确定 IGT 或 T2DM 患病率的终点。我们排除了病例报告、病例系列、社论和叙述性评论。排除了仅通过空腹血糖测量或自我报告诊断为 PCOS 或 IGT 或 T2DM 的研究。我们使用基于纽卡斯尔-渥太华量表(NOS)的预先确定的标准评估纳入研究的方法学质量。数据以随机效应荟萃分析的比值比(OR)(95%CI)表示,采用 Mantel-Haenszel 方法。我们使用亚组和荟萃回归分析评估人口统计学和临床因素对异质性的贡献。
我们审查了 4530 项研究,并在最终分析中纳入了 40 项符合条件的研究。在对质量研究进行荟萃分析时,患有 PCOS 的女性 IGT 的患病率增加(OR=3.26,95%CI:2.17-4.90)和 T2DM(OR=2.87,95%CI:1.44-5.72),这与种族有关(IGT:亚洲 5 倍,美洲 4 倍,欧洲 3 倍),肥胖患者更高,而在使用自我报告或行政数据诊断糖尿病的研究中则增加一倍。在 BMI 匹配的亚组中,种族相关差异仍然具有统计学意义。荟萃回归未显示异质性的明确促成因素。
我们的研究结果强调了 PCOS 作为糖基化受损的一个原因的重要性,IGT 和 T2DM 的患病率更高。它们支持种族和肥胖的相关性,并强调需要准确的糖尿病诊断方法。
CRD42017056524。